New POSLUMA Data at ASCO GU Promises to Sharpen Prostate Cancer Detection

BOSTON, MA – February 18, 2026

The world of oncology is turning its attention to San Francisco, where Blue Earth Diagnostics is poised to unveil a suite of new data on its advanced prostate cancer imaging agent, POSLUMA® (flotufolastat F 18). The presentations, scheduled for the upcoming ASCO 2026 Genitourinary Cancers Symposium (ASCO GU), are expected to provide significant new insights, including the results of a first-of-its-kind head-to-head comparison that could reshape clinical practice and influence patient care.

The Quest for Clarity in Prostate Cancer Detection

Prostate cancer diagnosis and management have long been fraught with challenges, particularly when detecting the disease's recurrence. A rising prostate-specific antigen (PSA) level after treatment can signal a return of the cancer, but pinpointing its exact location, especially when the PSA is very low, has been a persistent hurdle for conventional imaging like CT and bone scans. This is where positron emission tomography (PET) targeting the prostate-specific membrane antigen (PSMA) has emerged as a revolutionary tool, offering far greater sensitivity.

However, not all PSMA PET agents are created equal. A common technical challenge is the agent's excretion through the urinary tract. This can create a "halo" of high radioactivity in the bladder and pelvis, potentially masking small but clinically significant cancer lesions in the very region where recurrence is common. The upcoming ASCO GU symposium will feature the first intra-patient, head-to-head study comparing the urinary radioactivity of POSLUMA against its main competitor, piflufolastat F 18. If POSLUMA demonstrates significantly lower urinary excretion, it could translate to clearer, more easily interpretable images, giving clinicians a more confident view of potential disease and enabling more precise, targeted salvage therapies.

A High-Stakes Showdown in Molecular Imaging

The presentation of direct comparative data marks a significant strategic maneuver by Blue Earth Diagnostics, a subsidiary of the global imaging leader Bracco. The PSMA PET imaging market has seen rapid growth, with piflufolastat F 18, marketed as PYLARIFY® by Lantheus, securing a strong foothold. By commissioning and presenting a head-to-head study, Blue Earth is directly challenging the incumbent and aiming to carve out a distinct clinical advantage for POSLUMA.

This is not just an academic exercise; it is a battle for clinical preference and market share. For physicians, comparative evidence is the gold standard. A demonstrable advantage in image quality, particularly in the difficult-to-image pelvic region, could be a compelling reason to choose one agent over another. The results from this study, to be presented by Dr. Brian T. Helfand of Endeavor Health, are therefore highly anticipated by clinicians, industry analysts, and healthcare investors alike, as they could influence diagnostic pathways and purchasing decisions across healthcare systems.

Bolstering the Evidence: Beyond the Head-to-Head

Beyond the high-profile comparator study, Blue Earth is reinforcing the clinical dossier for POSLUMA with a series of post-hoc analyses from its pivotal Phase 3 LIGHTHOUSE and SPOTLIGHT studies. These presentations aim to deepen the understanding of POSLUMA's performance across the entire spectrum of prostate cancer care.

One analysis from the LIGHTHOUSE study, to be presented by Dr. Devaki Shilpa Surasi from The University of Texas MD Anderson Cancer Center, will compare POSLUMA's diagnostic performance directly against conventional imaging for detecting pelvic lymph node metastases in men with newly diagnosed cancer. This is critical for initial staging, as accurately identifying the spread of cancer from the outset determines the most appropriate initial treatment strategy, from surgery to radiation and systemic therapy.

Further analyses from the SPOTLIGHT study, to be presented by Dr. Ashesh Jani from Emory University's Winship Cancer Institute, will focus on two key areas. The first compares POSLUMA to conventional imaging in men with biochemical recurrence, adding to the body of evidence supporting its use in this common clinical scenario. The second delves specifically into the detection of bone metastases in men with low PSA recurrence—a crucial area, as bone is a common site of spread that can significantly impact prognosis and treatment.

"These presentations reflect our ongoing commitment to advancing molecular imaging with high-quality evidence that can help inform clinical decision-making, particularly in scenarios where earlier or clearer detection may influence patient management," said Marco Campione, President and CEO of Blue Earth Diagnostics, in a statement accompanying the announcement.

From Clinical Data to Clinical Practice

The ultimate goal of this research is to improve outcomes for the hundreds of thousands of men diagnosed with prostate cancer each year. The data to be presented at ASCO GU holds the potential to do just that by empowering physicians with a more precise diagnostic tool. Clearer imaging that can detect smaller amounts of cancer earlier allows for more confident decision-making.

For a patient with a suspected recurrence, this could mean the difference between a "watch and wait" approach filled with uncertainty and a targeted radiation plan aimed directly at a confirmed lesion. For a newly diagnosed patient, it could mean avoiding unnecessary treatments or, conversely, ensuring a more aggressive therapy is initiated when occult metastatic disease is found that would have been missed by older imaging techniques.

This wealth of new clinical data also plays a critical role in the broader healthcare ecosystem. Robust evidence is the foundation upon which regulatory bodies and, crucially, reimbursement providers like the Centers for Medicare & Medicaid Services (CMS) and private payers make their coverage decisions. By demonstrating clear clinical utility and potential advantages, Blue Earth strengthens the case for broad and consistent access to POSLUMA for all patients who could benefit. As the oncology community gathers in San Francisco, the data presented on POSLUMA will be a key part of the larger conversation about the future of precision oncology, where seeing the enemy with greater clarity is the first and most critical step toward defeating it.